Connect with us

Press Release

CMS’s (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

Published

on

SHENZHEN, CHINA China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world’s largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies.

 

About CMS-D008

CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection. It targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of INHBE-encoded Activin E protein, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. It demonstrates the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. Currently, the Phase I clinical trial of CMS-D008 in healthy subjects is progressing steadily. In the future, it may be developed for the treatment of abdominal obesity and related metabolic diseases.

 

CMS-D008 has demonstrated encouraging preclinical data. The preclinical research results of CMS-D008 presented at the ADA Scientific Sessions showed that in obese animal models, CMS-D008 efficiently and sustainably suppressed INHBE expression, achieving significant weight loss and fat reduction while sparing muscle mass, with a favorable safety profile, indicating the potential for healthy weight loss. Details are as follows:

Title: CMS-D008 specifically silences INHBE mRNA, delivering fat-selective weight loss in preclinical study

Presentation Number: 3079-LB

Presentation format: Poster

Date/Time: June 7, 2026 01:30 PM – 02:30 PM (Local Time)

Location: Hall D-E

Results:

  1. In a high-fat diet-induced model of humanized INHBE obese mouse (hINHBE DIO mouse), CMS-D008 significantly reduced hepatic INHBE mRNA expression and serum Activin E protein levels, leading to marked decreases in body weight, total body fat, and regional fat mass while preserving lean mass.
  2. In a model of obese cynomolgus macaque, CMS-D008 also significantly reduced hepatic INHBE mRNA expression and plasma Activin E protein levels, and effectively suppressed weight gain induced by a sustained high-fat diet.

 

The inclusion of these findings at the ADA Scientific Sessions reflects the international academic community’s interest in the scientific value and clinical potential of CMS-D008 in

3the field of obesity/metabolic treatment. CMS-D008 will synergize with CMS-D005, a self-developed, clinical-stage innovative drug (a GLP-1R/GCGR dual agonist), to deliver highly effective weight-loss benefits and long-term maintenance of results, providing patients with a more comprehensive and innovative treatment option.

 

CMS is committed to in-house R&D as a core driver of its long-term growth and continues to advance innovation in cutting-edge therapeutic areas. Currently, 6 self-developed products with global rights, including CMS-D008, have entered the clinical stage, with over 20 additional self-developed projects steadily progressing in preclinical research. Looking ahead, the Group will continue to focus on unmet medical needs, efficiently advance product R&D and commercialization, and bring more comprehensive and innovative therapies to benefit broad patient population.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

23 Years, One Question: “Diaoyu Dao: Small Islands, Big Stakes” — A CGTN Documentary

Published

on

This article was produced to coincide with the release of CGTN’s new documentary Diaoyu Dao: Small Islands, Big Stakes. Inspired by one of the documentary’s stories, it follows Chinese scholar Wu Tianying’s 23-year pursuit of historical truth, showing how one man’s lifelong research underscores the enduring importance of historical evidence in understanding the Diaoyu Dao (known in Japan as the Senkaku Islands) dispute.


https://youtu.be/ohsuJMRJ7GM?si=k2LX9Hv-oZKpIwMw

“In the years before the First Sino–Japanese War, were Diaoyu Dao and its affiliated islands terra nullius – or were they already Chinese territory?”

At 90 years old, Professor Wu Tianying still asks that question slowly and carefully.

In a quiet study lined with books and documents, the veteran Chinese scholar opens a worn manuscript – “On the Territorial Sovereignty over the Diaoyu Islands Prior to 1894.”

It took him 23 years to complete and publish.

For Wu, the book was never simply an academic study.

“It was a commitment to sovereignty,” he says in CGTN’s new documentary “Diaoyu Dao: Small Islands, Big Stakes.”

Part Two of the documentary, “Behind Closed Doors,” follows Wu’s decades-long effort to trace the historical origins of the Diaoyu Dao dispute – not through slogans or political rhetoric, but through archives, maps and an unexpected intellectual exchange with Japanese scholars.

The deeper I searched…”

Wu Tianying belongs to one of the earliest generations of Chinese scholars to systematically study the Diaoyu Dao issue after China and Japan normalized relations.

At the center of his research was one key argument.

Japan’s claim over the islands rests partly on the concept of terra nullius – land belonging to no state before incorporation.

If the islands were terra nullius, they could, in principle, be claimed through occupation under international law.

In his research, Wu asked whether Japan’s incorporation of Diaoyu Dao during the late 19th century was truly unrelated to its war against the Qing government.

His work brought him into contact with Japanese historian Kiyoshi Inoue.

Inoue had originally sought to prove that the islands belonged to Japan.

Years of studying historical materials led him to  a different conclusion.

“The deeper I searched,” Inoue says in archival footage in the documentary, “the clearer it became that the Senkaku Islands (Diaoyu Dao) are China’s territory rather than terra nullius. They have nothing to do with Japan.”

In 1995, Inoue received a copy of Wu’s book.

A year later, Inoue wrote back, praising Wu’s work as a “thorough and scientific rebuttal” of Japanese claims represented by scholars such as Toshio Okuyama.

The two scholars came from different countries and very different historical backgrounds. But both believed historical arguments had to be tested against evidence.

Still waiting for an answer

But Behind Closed Doors is not only about the past.

It also asks what happened to the political understanding that once existed between China and Japan over the Diaoyu Dao issue.

Wu Tianying reflects on Japanese scholars who once warned against pushing the dispute further.

He says he is still watching how Japan’s current political leadership responds to those earlier voices inside Japan itself.

And he is still waiting for an answer.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

All Thingz Electric Expands EV Charger Installation Services Across South Orange County to Meet Growing Demand

Published

on

Aliso Viejo, California, United States, 25th Jul 2026 – All Thingz Electric, a licensed electrical contractor serving residential and commercial clients throughout Orange County, today announced the expansion of its electric vehicle (EV) charger installation services to meet surging demand across South Orange County communities. As EV adoption accelerates throughout the region, All Thingz Electric is positioning itself as the go-to resource for homeowners navigating the transition to home charging.

Orange County’s EV Surge

California leads the nation in EV adoption, and Orange County communities, particularly Aliso ViejoMission ViejoIrvine, and Laguna Niguel, have seen significant growth in electric vehicle registrations over the past two years. With that growth comes increased demand for Level 2 home charging solutions, which can charge most EVs overnight and are far more efficient than standard 120V outlets.

“We’re getting more calls about EV chargers than almost anything else right now,” said Anthony Feeney, founder and certified journeyman electrician at All Thingz Electric. “A lot of homeowners buy an EV and assume the outlet in the garage will work fine, and it does, slowly. But once they understand what a dedicated Level 2 charger can do, they want it installed right away. It changes how convenient owning an EV actually is.”

What the Installation Involves

A Level 2 EV charger installation typically involves running a dedicated 240V circuit from the electrical panel to the garage or charging location. In some cases, particularly in older homes, a panel upgrade may be required first to accommodate the added load. All Thingz Electric’s technicians evaluate each home’s existing infrastructure before beginning any work, ensuring the right solution is specified the first time. An electrical inspection and code compliance check is included to ensure the installation meets all local requirements.

All Thingz Electric installs chargers from all major brands and can coordinate directly with utility companies on applicable rebate programs.

A Full-Service Electrical Partner

Beyond EV charging, All Thingz Electric offers a comprehensive range of residential electrical services including whole-house surge protectionoutdoor and landscape lighting installationbackup generator installation, and 24/7 emergency electrical services. Free quotes are available for all services, and all work is backed by a 100% satisfaction guarantee.

“Orange County homeowners expect quality, and we deliver that on every job,” Feeney said. “Whether someone needs a charger installed or their whole panel replaced, we treat every project like it’s our own home.”

About All Thingz Electric

All Thingz Electric is a licensed electrical contractor founded by Anthony Feeney, a certified journeyman electrician, serving residential and commercial clients throughout Orange County. The company is based in Aliso Viejo and serves Laguna Niguel, Mission Viejo, Irvine, Lake Forest, Dana Point, Laguna Beach, and surrounding communities. Services include EV charger installationelectrical panel upgradeswhole-house surge protectionlighting servicesrewiring, and emergency electrical response. Free quotes are available; 100% satisfaction guaranteed.

Media Contact: All Thingz Electric Team
Phone: 949 426-7977
Website: https://allthingzelectric.com
Email: contact@allthingzelectric.com
Address: 26791 Aliso Creek Rd. #1015, Aliso Viejo, CA 92656

Media Contact

Organization: All Thingz Electric

Contact Person: Anthony Feeney

Website: https://allthingzelectric.com/

Email: Send Email

Contact Number: +19497103564

Address:26791 Aliso Creek Rd #1015

City: Aliso Viejo

State: California

Country:United States

Release id:47587

The post All Thingz Electric Expands EV Charger Installation Services Across South Orange County to Meet Growing Demand appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

RELVE Q2 Report Reveals AI Hype Gap After Analyzing 1.59M Data Points and 23,000 Tools

Published

on

182 AI developments shipped last quarter. Only 29 required a decision from a SaaS operator. RELVE’s Q2 report “The State of AI for SaaS Companies” analyzed 1.59 million data points across 9 categories and 69 attributes to highlight the hype and the gap.

United States, 25th Jul 2026 – Eighty-four percent of the AI news that reached SaaS founders last quarter changed nothing about how they build, staff, budget, or buy. That’s the central finding of The State of AI for SaaS Companies, RELVE’s Q2 2026 report released 23-July-2026, built on 23,000+ tools reviewed and 1.59 million data points assessed.

Every item was sorted into three labels: 72 Noise, 81 Watch, and 29 Signals. A Signal is a named, verifiable change worth acting on now. Watch items are patterns still forming, with a clear trigger that could turn them urgent. Noise is real news with no consequence for how a company operates.

Coverage did not track with consequence. The three most-covered companies of the quarter took 28.9% of all coverage yet produced zero Signals. Meanwhile, more than a third of the quarter’s Signals had no single company behind them at all. The report found the loudest stories were rarely the ones that mattered most, and that attention and consequence often pointed in opposite directions.

RELVE Q2 Report

The 29 Signals grouped into three shifts. The model layer stopped being the moat as frontier-grade output got cheap and interchangeable. Agents began arriving inside company systems before the governance did, often switched on by default in tools teams already run.

And meeting and notetaker tools started turning into the system of record where a company’s decisions, context, and institutional memory live.

Each shift carries a cost if ignored. On AI governance, RELVE cites IBM research showing that high shadow AI use added $670,000 to the average data breach, and that most organizations breached through AI lacked proper access controls.

On skills, the wage premium for AI-fluent roles reached 62% in 2026, more than double what it was two years earlier. On the model layer, cheaper inference reset the build-versus-buy math for nearly every AI-using company.

The report also reads the macro picture on enterprise AI adoption from the major research firms. Adoption is close to universal at 88%, yet only a small share of organizations capture most of the value.

RELVE draws a distinction here: the big firms survey thousands of executives to measure intent, while RELVE tracks what actually shipped and rules on which developments change what an operator does. Its conclusion is that the bottleneck is now workflow, governance, and people, not the technology itself.

The tool review is the foundation under the report. RELVE assessed those tools across 9 categories on 69 attributes, then shortlisted 1,881 across six categories. Nearly 90% of that shortlist was built as AI from the start, with the rest being established tools that added AI later. Marketing and creative made up the two largest categories.

Funding followed a similar pattern of concentration. Among the shortlisted tools, 695 have recorded funding totalling $93.56 billion, with the top ten accounting for about 58% of the total and a single company representing roughly a third of everything tracked. Engineering and operations pulled the most capital by category, while marketing tools, despite being the largest group by count, raised the least.

Events told the same story as the news. RELVE assessed 26 industry conferences during the quarter and found only two produced a Signal. Several more carried announcements worth a founder’s attention without crossing the bar, and many were covered elsewhere purely as spectacle. 

The report sorts every event by consequence instead of size, and closes the section with the Q3 dates worth holding.

The report ends with a set of concrete moves for operators, split into what to act on this quarter and what to plan for next.

The near-term list covers checking exposure to shifting engineering-tool pricing, running an inventory of enterprise AI agents that can take autonomous action, and setting a permission and data-access rule for each. RELVE frames this as an AI agent governance problem most teams have not solved yet.

The forward list points to building around cheap and interchangeable models rather than scarce ones, and reassessing vendor lock-in as meeting tools consolidate into a system of record.

The full report, including the function-by-function breakdown for marketing, engineering, operations, HR, and creative, is available on the RELVE site.

About RELVE

RELVE is an AI intelligence platform for AI trends and tools, built for SaaS founders and their core teams across marketing, HR, operations, engineering, and creative. It filters signal from noise: verified news sorted by what matters, tools ranked by data rather than who paid for the listing, and Signals that brief every function, not just the person at the top. Learn more at relvehq.com.

Users can follow RELVE on:

LinkedIn: https://www.linkedin.com/company/relve

X: https://x.com/Relve_official

Media Contact

Organization: RELVE

Contact Person: RELVE

Website: https://relvehq.com/

Email: Send Email

Country:United States

Release id:47458

The post RELVE Q2 Report Reveals AI Hype Gap After Analyzing 1.59M Data Points and 23,000 Tools appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST